Recognify Life Sciences Inc.

Neuropsychiatry

Research activity is centered on schizophrenia, with attention to symptoms affecting cognition, function, and daily living. The sponsor’s clinical interest includes treatment areas linked to cognitive impairment associated with schizophrenia and related neuropsychiatric outcomes.

  • Schizophrenia
  • Cognitive impairment
  • Neuropsychiatric disorders

The portfolio reflects a focus on clinical areas where cognitive performance is a central therapeutic concern.

Cognitive Disorders

The sponsor also studies broader cognitive disorder domains, with emphasis on deficits in attention, memory, and executive function. This includes conditions in which impaired cognition is a major clinical burden and a target for therapeutic intervention.

  • Cognitive disorder
  • Attention
  • Memory

These interests place cognition at the center of the sponsor’s medical focus.

Central Nervous System Therapeutics

Clinical research activity extends into central nervous system therapeutics, particularly areas involving neurocognitive symptoms within psychiatric illness. The sponsor’s work is aligned with treatment development for disorders where brain-based functional outcomes are clinically significant.

  • Central nervous system
  • Neurocognitive symptoms
  • Psychiatric illness

This includes therapeutic interest in improving cognition-related outcomes in mental health conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

    Not recruiting

    Investigated diseases:
    Bulgaria Czechia Poland